Search Results for: The Gene Editing Institute of
Articles
The Gene Editing Institute of Christiana Care’s Helen F. Graham Cancer Center & Research Institute Signs Agreement With ABS September 18, 2017
To accelerate the development of next-generation cancer therapies, the Gene Editing Institute of the Helen F. Graham Cancer Center & Research...Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy Designation for Severe Sickle Cell Disease Treatment October 16, 2023
Editas Medicine, Inc. recently announced the US FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to EDIT-301, an investigational, gene-editing...Precision BioSciences Announces In Vivo Gene Editing Collaboration With Novartis June 22, 2022
Precision BioSciences, Inc. recently announced it has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis Pharma….
Editas Medicine & Immatics Enter Strategic Research Collaboration & Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies & Gene Editing for the Treatment of Cancer June 7, 2022
Editas Medicine, Inc. and Immatics N.V. recently announced the two companies have entered into a strategic research collaboration and licensing agreement to combine gamma-delta T cell adoptive cell therapies and….
GENE EDITING TECHNOLOGY - Harnessing a Cell’s Natural DNA Repair Process to Develop Medicines With Higher Levels of Precision & Durability March 1, 2022
Mariana Nacht, PhD, reviews a new gene editing approach that harnesses a cell’s natural DNA repair process, known as homologous recombination, to insert a corrective copy of the gene (or transgene) at a precise spot in a patient’s genome.
Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline December 13, 2021
Precision BioSciences, Inc. recently announced program updates across its allogeneic CAR T cell therapy pipeline, including updated data for its Phase 1/2a clinical study of PBCAR0191 with enhanced lymphodepletion (eLD) presented at….
GENE-EDITING TECHNOLOGY - The Importance of Assessing Off-Target Effects of CRISPR Gene Editing August 31, 2020
Mark Behlke, MD, PhD, says gene editing raises legitimate questions and fears about possible risks and misuse, and given the relative technical ease and low cost of CRISPR gene editing, this is likely to find widespread use in both medicine and agriculture.
Sarepta Announces Agreement With Nationwide Children’s Hospital for Rights to its Gene Therapy Program May 13, 2019
Sarepta Therapeutics, Inc. recently announced it has recently signed an agreement with the Research Institute at Nationwide Children’s Hospital (Nationwide...Amfora Licenses Gene-Editing Technology April 3, 2019
Amfora recently announced it has reached a non-exclusive research and commercial license agreement with Corteva Agriscience, the Agriculture Division of...GENE-EDITING TECHNOLOGY - How CRISPR-Cas9 Technology Will Play a Vital Role in the Future of Human Therapeutics & Drug Discovery January 8, 2018
Kevin Holden, PhD, explores how this technology can be utilized in research efforts toward the development of new therapies and how it will play a vital role in the future of biopharma and drug discovery.